Mark Beggs, COO
Mark Beggs joined NCIMI in September 2020 as Programme Manager and is now our COO. He holds a PhD in Clinical Biochemistry and a BA in Biochemistry both from Oxford University.
Prior to NCIMI, he was CEO of UK Biocentre and Stratified Medicine Scotland, a nationally co-ordinated genomic medicine initiative, and previously as Programme Manager of Pfizer’s (former Wyeth) Translational Medicine Research Collaboration programme.
Before this, Mark was Head of Consulting at TAP Biosystems (as The Automation Partnership) in Cambridgeshire UK for eight years where he led a consulting team in delivering major change programmes for clients within Pharma Discovery and Biological production with particular focus on the application of manufacturing consultancy techniques in a Pharma Discovery environment.
Mark has an additional ten year’s direct experience in early-stage Pharma Discovery roles, having worked variously for GSK (as Glaxo) in North Carolina USA, Astra Zeneca (as Zeneca) in Alderley Park, UK and J&J in Beerse, Belgium where he was Director of HTS. In these roles, he developed significant experience in the design and deployment of automated systems for life science applications and in-process scale-up.
Mark Beggs believes NCIMI is important as it is delivering value and creating opportunities.
Mark likes to mess around with boats and big lumps of wood